Rare Impact Awards – NORD’s Rare Impact Awards
This very special event will celebrate NORD’s legacy and achievements, and honor those individuals and organizations doing remarkable work on behalf of the rare disease community.
This very special event will celebrate NORD’s legacy and achievements, and honor those individuals and organizations doing remarkable work on behalf of the rare disease community.
Submission deadline – June 12, 2024 NORD notifies authors of acceptance – July 23,
/PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing novel treatments for severe neurodegenerative diseases,…
Website Disclaimer The information provided in the Dysautonomia Foundation web site is intended to educate the reader about certain medical conditions and certain possible treatments.…
“Every 90 Minutes” has been a tagline that organizations have used for over a decade to describe how often someone dies from ALS in the…
Partnership to expand applications of DNA break-mapping technology and advance understanding of genomic instability in development of the neurodegenerative disease amyotrophic lateral sclerosis
There is a lot that the Bears Hall of Famer can’t do anymore, but he can still connect with the people who have been important…
Gland Pharma Ltd. announced on Tuesday that the US health government has approved its generic Edaravone injection for the treatment of amyotrophic lateral sclerosis.
This very special event will celebrate NORD’s legacy and achievements, and honor those individuals and organizations doing remarkable work on behalf of the rare disease…
Dr. Smith-Whitley, pediatric hematologist at the Children’s Hospital of Philadelphia, discusses the advances in sickle cell disease.
The All of Us Research Program’s database of more than 770,000 people is proving to be a treasure trove for health researchers, who are using…